Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- PL Intelligence
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- PL Intelligence
- Overview
- Industry news
- Deals review
- Press releases
- Articles
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
25 and 50 mg diclofenac K film coated immediate release tablets More
Using a lamellar structure as a delivery system, the Sulidin® Nimesulide LPS gel provides enhanced percutaneous penetration of Nimesulide and reduced yellow staining on the skin. LPS Technology worldwide patents are pending. More
Diclofenac transdermal delivery system for the treatment of inflammatory and painful conditions More
The First Line of Therapy in Severe Migraine Attacks More
25mg dosage strenght for the OTC market in film coated tablets More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Capsaicin, the active ingredient found in red-hot peppers, is used mainly for the relief of chronic pain of rheumatoid arthritis and osteoarthritis More
25mg dosage strenght for the OTC market More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints. More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2009 Pharmalicensing, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us